AMENDMENT NO. 1 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT
EXIBIT 10.39(a)
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND (II)
WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.
AMENDMENT NO. 1
TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT
This Amendment No. 1 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and
entered into as of April 4, 2019 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Xxxxxxxx Cancer Center (“MD Xxxxxxxx”), a member institution of The University of Texas System (“System”).
RECITALS
| A. |
Cell Source and MD Xxxxxxxx entered into a Veto Cell Production and Clinical Trial Program Agreement dated February 19, 2019 (the “Agreement”).
|
| B. |
Cell Source and MD Xxxxxxxx wish to amend the terms of the Agreement as set forth below.
|
NOW, THEREFORE, it is hereby agreed as follows:
| 1. |
Exhibit B of the Agreement shall be revised in its entirety with the attached Amended Exhibit B.
|
| 2. |
Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as
provided therein.
|
IN WITNESS WHEREOF, Cell Source and MD Xxxxxxxx have entered into this Amendment effective as of the date first
set forth above.
|
CELL SOURCE
|
THE UNIVERSITY OF TEXAS
|
||
| |
M.D. XXXXXXXX CANCER CENTER | ||
|
By /s/ Xxxxxx Xxxxxxx
|
By /s/ Xxxx Xxxx
|
||
|
Xxxxxx Xxxxxxx
|
Name: Xxxx Xxxx
|
||
|
Chief Executive Officer
|
Title: Director, Research Funding Programs
|
||
|
Date: April 4, 2019
|
Date: April 19, 2019
|
||
|
Read & Understood:
|
|||
|
/s/ Xxxxxxx Xxxxxxxx
|
|||
|
Xx. Xxxxxxx Xxxxxxxx
|
|||
|
Principal Investigator
|
EXIBIT 10.39(a)
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND
(II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.
Amended Exhibit B
PAYMENT
PLAN
Payment Terms
Payments shall be made by Electronic Funds Transfer via the Automated Clearing House (ACH), which is MD Anderson’s
preferred method to receive payments, or by wire or check. With each payment, Sponsor shall provide the appropriate MD Xxxxxxxx Research Contracts Tracking Number (RCTS # 56497 and MD Anderson’s invoice number (GRNXXXXXX) if applicable. To minimize
any delays in receiving and applying payments, Sponsor will provide the following information via email transmission to XX_Xxxxxxxx@xxxxxxxxxx.xxx at the time
payment is issued to MD Xxxxxxxx:
|
·
|
the name of the bank submitting the payment,
|
|
·
|
RCTS number : [ ]
|
|
·
|
amount of the payment,
|
|
·
|
MD Xxxxxxxx Principal Investigator Xxxxxxx Xxxxxxxx MD
|
|
·
|
Sponsor contact name or email regarding Payments
|
|
·
|
Sponsor Protocol number 2018-0221
|
Electronic Payments (ACH and Wire)
Bank Name: XX Xxxxxx Xxxxx Bank, N.A
Bank Address: 000 Xxxxxx
Xxxxxxx, Xxxxx 00000
Account Name: Univ of Texas MD Xxxxxxxx Cancer Center
Account Number: [ ]
Domestic Banks: ABA Routing Number: 000000000 (ACH) 000000000 (Wire)
Internal Swift: XXXXXX00 (international)
Checks should be mailed to:
The University of Texas
MD Xxxxxxxx Cancer Center
Attn: Grants and Contracts RCTS # 56497
X.X. XXX 0000
Xxxxxxx, Xxxxx 00000-0000
If Sponsor issues a payment to MD Xxxxxxxx that combines payments for multiple studies, Sponsor will provide a detail
listing including MD Xxxxxxxx Principal Investigator and the amount of payment for each study via email transmission to XX_Xxxxxxxx@xxxxxxxxxx.xxx upon issuing payment to MD Xxxxxxxx.
EXIBIT 10.39(a)
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND
(II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR.
|
EXHIBIT B- BUDGET
Funding Agency:
|
Cell Source Limited
|
|
|
Principal Investigator:
|
Xxxxxxxx, Xxxxxxx
|
|
|
Title:
|
Role of Veto Cells in Haploidentical Transplantation for Myeloma
|
|
|
Project Dates:
|
TBD
|
|
|
Protocol(s)
|
2018-0221
|
3% increase
|
|
Total Patients
|
[_____]
|
|
|
*
|
|
|
Year 1
|
Year 2
|
|||||||||||||||||||||||||||||||||
|
Personnel
|
Base Salary
|
Cal Mths.
|
Effort
|
Salary
|
Fringe
|
Total
|
Total
|
Grand Total
|
||||||||||||||||||||||||||
|
[
|
]
|
[ |
]
|
[ |
]
|
[[
|
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
|||||||||||||||||
| [ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
|||||||||||||||||
| [ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
|||||||||||||||||
| [ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
|||||||||||||||||
| [ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
[ |
]
|
|||||||||||||||||
|
Salary Total
|
$
|
[ |
] |
$
|
[ |
]
|
[ |
]
|
||||||||||||||||||||||||||
|
Equipment
|
$
|
--
|
$
|
--
|
--
|
|||||||||||||||||||||||||||||
|
Consultant Costs
|
$
|
$ | ||||||||||||||||||||||||||||||||
|
Total
|
$
|
--
|
$
|
--
|
$
|
--
|
||||||||||||||||||||||||||||
|
Supplies
|
||||||||||||||||||||||||||||||||||
|
Travel
|
||||||||||||||||||||||||||||||||||
|
Total
|
||||||||||||||||||||||||||||||||||
Patient Care Costs
CTRC Admin Fee
Other Direct Costs
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]***
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
| [ |
]
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
||||||||||||
|
Total
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
|||||||||||
|
Direct Costs
|
|||||||||||||||||
|
Indirect Costs [ ]%
|
$
|
[________]
|
$
|
[_________]
|
$
|
[_________]
|
|||||||||||
|
Total Costs
|
$1,103,978.68
|
$811,249.33
|
$1,915,228.01
|
||||||||||||||
|
***[ ].
|
|||||||||||||||||
